Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.48 USD
Change Today +0.54 / 9.09%
Volume 471.1K
NEO On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for neogenomics inc (NEO)

Neogenomics Inc. appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total $33.7M USD. Accounts Receivable are typical for the industry, with 82.01 days worth of sales outstanding. Last, Neogenomics Inc. is among the least efficient in its industry at managing inventories, with 19.36 days of its Cost of Goods Sold tied up in Inventories.
Currency in
Millions of US Dollars
As of:Dec 31
2011
Reclassified
Dec 31
2012
Dec 31
2013
Dec 31
2014
4 Year
Trend
Assets    
Cash and Equivalents2.61.94.833.7
TOTAL CASH AND SHORT TERM INVESTMENTS2.61.94.833.7
Accounts Receivable7.914.018.720.5
Other Receivables0.1------
TOTAL RECEIVABLES8.014.018.720.5
Inventory1.21.92.32.6
Prepaid Expenses0.80.8----
Deferred Tax Assets, Current----0.60.8
Restricted Cash0.5------
Other Current Assets----1.11.1
TOTAL CURRENT ASSETS13.218.627.558.7
Gross Property Plant and Equipment13.318.924.234.9
Accumulated Depreciation-6.7-10.3-14.5-19.8
NET PROPERTY PLANT AND EQUIPMENT6.68.69.715.1
Goodwill------2.9
Other Intangibles--2.82.64.2
Other Long-Term Assets0.10.10.20.1
TOTAL ASSETS19.930.139.981.1
    
LIABILITIES & EQUITY    
Accounts Payable2.53.64.26.3
Accrued Expenses2.93.53.15.1
Short-Term Borrowings3.98.54.3--
Current Portion of Long-Term Debt/Capital Lease2.12.22.83.2
Current Portion of Capital Lease Obligations2.12.22.83.2
TOTAL CURRENT LIABILITIES11.417.814.314.6
Capital Leases2.63.13.35.3
Deferred Tax Liability Non-Current----0.60.8
TOTAL LIABILITIES14.120.918.220.7
Common Stock0.00.00.00.1
Additional Paid in Capital28.531.742.279.8
Retained Earnings-22.6-22.6-20.5-19.4
TOTAL COMMON EQUITY5.99.221.760.4
TOTAL EQUITY5.99.221.760.4
TOTAL LIABILITIES AND EQUITY19.930.139.981.1
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $6.48 USD +0.54

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $9.75 USD +0.28
Enzo Biochem Inc $2.92 USD +0.03
Foundation Medicine Inc $23.65 USD +0.72
Psychemedics Corp $11.04 USD -0.09
Rosetta Genomics Ltd $2.46 USD +0.03
View Industry Companies
 

Industry Analysis

NEO

Industry Average

Valuation NEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.8x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.